Retatrutide is a triple agonist, acting on the GLP-1, GIP and glucagon receptors. It has completed phase 3 trials and is not approved for sale anywhere. Sold as research material, not as a medicine.
Bio-Peptide, 20 mg
800,00 złAdd to cart5 in stock (can be backordered)
Genheal, 20 mg
800,00 złAdd to cartAvailable on backorder
What is in the vial
Two manufacturers offer retatrutide here, both in 20 mg vials. In the trials the highest dose was 12 mg per week, so a single vial holds more than a week of the largest dose studied. A 20 mg vial with 2 ml of bacteriostatic water gives 10 mg per millilitre, and at that concentration the volumes involved are very small: the arithmetic and its conversion into syringe units are in the guides on reconstitution and syringe units.
What the phase 3 programme showed
In TRIUMPH-1, with 2,339 participants, average weight reduction after 80 weeks was 25.0 percent at 12 mg against 3.9 percent on placebo, counted by the treatment-regimen estimand. Counted by the efficacy estimand the same trial gives 28.3 percent against 2.2 percent. In an extension to 104 weeks, in the subgroup with a baseline body mass index of 35 or above, it reached 30.3 percent.
TRIUMPH-2, in people with type 2 diabetes, gave up to 20.8 percent, with glycated haemoglobin falling 1.4 to 1.6 points from a baseline of 7.7 percent. TRIUMPH-3, in severe obesity with cardiovascular disease, gave 22.6 percent.
Side effects and status
At the highest dose 42.4 percent reported nausea, 32.0 percent diarrhoea and 25.3 percent vomiting, and 11.3 percent stopped treatment because of side effects. Retatrutide has no approval in the European Union or the United States; the manufacturer has announced plans to file in the United States in the first quarter of 2027. Full details are in the retatrutide guide.
What “not approved” means here
It is not the same as untested. Retatrutide has more published phase 3 data behind it than most molecules in this catalogue have data of any kind. What it does not have is a regulator’s decision on the balance of benefit and risk, a licensed manufacturer, an approved dose or product information. Those are separate things and the trial results do not substitute for them. How the three incretins compare is in the comparison guide.
Handling and verification
Supplied as lyophilised powder. Storage rules change once it is dissolved: see storage. Check the code under the hologram and the batch certificate as described in check your product. We ship within Poland and abroad; outside Poland the cost is quoted individually, depending on weight and destination country. Details: shipping and payments.
Questions
How much weight did retatrutide produce in phase 3?
25.0 percent at 12 mg after 80 weeks in TRIUMPH-1 by the treatment-regimen estimand, and 30.3 percent at 104 weeks in the subgroup with a body mass index of 35 or above.
Is it approved anywhere?
No. The manufacturer has announced plans to file in the United States in the first quarter of 2027.
How common were side effects?
At the highest dose, nausea in 42.4 percent, diarrhoea in 32.0 percent and vomiting in 25.3 percent; 11.3 percent stopped treatment because of them.
Which of the three incretins is strongest?
By the published numbers retatrutide, but it has never been compared with tirzepatide head to head, and it is the only one of the three with no approval anywhere.